Study identifies perception gap in incidence, impact of CINV/RINV
the ONA take:
There is a perpetual gap between healthcare professionals and patient perceptions of incidence and impact on patients' daily life of chemotherapy- and radiotherapy-induced nausea and vomiting (CINV/RINV), according to findings presented at the joint Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) 2015 Annual Meeting on Supportive Care in Cancer in Copenhagen, Denmark.
Researchers found that oncologists and oncology nurses overestimate the incidence of CINV/RINV, but underestimate the effect that CINV/RINV has on patients' daily lives. Moreover, data showed that 28% of patients believe oncologists underestimate the impact of CINV/RINV on patients' daily lives.
Results also showed that physicians and nurses believe 60% of patients are fully compliant with physicians' and/or nurses guidelines for self-administration of anti-emetic medications; however, only 38% reported full compliance. Patients reported reluctance to increase pill burden and concern that swallowing would cause nausea/vomiting as reasons for non-compliance.
The findings suggest that the gap between physician and patient perceptions may result in inadequate management of patients' CINV/RINV.
There is a perpetual gap between healthcare professionals and patient perceptions of incidence and impact on patients' daily life of CINV/RINV.
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Immune Thrombocytopenia (Fact Sheet)
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|